GlassScriptPhysician profile
Obaid N Jafri
NPI 1972513562
$2,295.06
in general payments reported to CMS, 2019-2025
32 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $296 · 2021: $334 · 2022: $390 · 2023: $525 · 2024: $202 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.69 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $393.11 | 2019-2024 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $369.18 | 2019-2025 | Injectafer |
| Abbvie INC. | $263.13 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $119.69 | 2022-2025 | |
| Hologic Sales and Service, LLC | $117.85 | 2019-2023 | Acessa Provu System, Aptima |
| Minerva Surgical, INC | $110.23 | 2019-2025 | |
| Coopersurgical, INC. | $109.38 | 2019-2025 | Paragard T 380a, Ally II Ups |
| Sumitomo Pharma America, INC. | $87.76 | 2023-2024 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $68.21 | 2021-2022 | |
| Axonics, INC. | $57.48 | 2021-2022 | |
| Pfizer INC. | $55.29 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $51.66 | 2019-2020 | |
| Karl Storz Endoscopy-America | $47.98 | 2023 | N.A. |
| Biogen, INC. | $46.82 | 2024-2025 | Zurzuvae |
| Urovant Sciences INC | $37.22 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $33.70 | 2019-2020 | |
| Scynexis, INC. | $31.02 | 2022 | |
| Lupin INC. | $30.47 | 2020 | |
| Novo Nordisk INC | $29.27 | 2020-2023 | |
| Lilly USA, LLC | $23.27 | 2025 | Zepbound |
| Duchesnay USA Incorporated | $22.98 | 2019 | |
| Abbott Laboratories | $22.31 | 2024 | Proclaim |
| Organon LLC | $19.92 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.76 | 2020 | |
| Boston Scientific Corporation | $18.70 | 2019 | |
| Exeltis, USA INC. | $18.17 | 2021 | |
| Evofem Biosciences, INC. | $17.72 | 2021 | |
| Meditrina | $16.58 | 2024 | |
| Covidien LP | $15.58 | 2019 | |
| Teleflex LLC | $15.16 | 2021 | |
| Therapeuticsmd, INC. | $14.82 | 2019 | |
| Aspira Women'S Health INC | $11.64 | 2024 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Obaid Jafri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.